Schofield Christine, Chaudhuri K Ray, Carroll Camille, Sharma Jagdish C, Pavese Nicola, Evans Jonathan, Foltynie Thomas, Reichmann Heinz, Zurowska Laura, Soares-da-Silva Patrício, Lees Andrew
Research & Development Unit (Neurology), Royal Cornwall Hospitals Trust, Truro, Cornwall, TR1 3HD, UK.
Parkinson's Foundation Centre of Excellence, King's College Hospital & NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, WC2R 2LS, UK.
Neurodegener Dis Manag. 2022 Apr;12(2):77-91. doi: 10.2217/nmt-2021-0057. Epub 2022 Mar 21.
This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.
OPTIPARK研究的这项亚分析旨在证实opicapone在英国临床实践中对帕金森病伴运动波动患者的有效性和安全性，并评估opicapone对治疗成本的影响。患者接受在左旋多巴基础上加用opicapone治疗6个月。在3个月和6个月时评估临床结局，在6个月时评估治疗成本。大多数患者的总体状况在3个月时有所改善，6个月时报告有持续改善。opicapone在两个时间点均改善了运动和非运动症状，总体耐受性良好，并使总治疗成本降低了3719英镑。在左旋多巴基础上加用opicapone在英国临床实践中带来了临床改善并降低了治疗成本。
